Anika Fully Enrolls Second Phase III CINGAL Trial

Anika Therapeutics completed enrollment of 576 patients in its second pivotal Phase III trial evaluating CINGAL® hyaluronic acid/corticosteroid viscosupplement for the treatment of knee osteoarthritis symptoms.

CINGAL combines triamcinolone hexacetonide, an FDA-cleared steroid utilized to treat inflammation, with cross-linked,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us